Aurinia Pharmaceuticals (AUPH) Posts Wider Q2 Loss

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.26), $0.12 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $29 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• InMode expects Q2 revenue of $95.2M-$95.4M, full-year up to $375M
• EastGroup Properties (EGP) PT Raised at KeyBanc, Reflecting Improving Outlook